GlassScriptPhysician profile
Michael W Evans
NPI 1972782522
$1,715.28
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,008 · 2020: $325 · 2021: $88.00 · 2022: $158 · 2023: $99.53 · 2024: $36.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $71.31 · Food and Beverage: $64.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $71.31 |
| Food and Beverage | $64.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $228.10 | 2019-2023 | Imbruvica, Epkinly |
| Janssen Biotech, INC. | $222.23 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $197.32 | 2019-2024 | Keytruda, Welireg |
| Seagen INC. | $177.13 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $78.41 | 2020-2023 | |
| Genentech USA, INC. | $66.37 | 2019 | |
| Astellas Pharma US INC | $65.68 | 2019 | |
| Pfizer INC. | $63.10 | 2019-2022 | |
| Kite Pharma, INC. | $62.79 | 2021-2023 | |
| Amgen INC. | $58.99 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.07 | 2019 | |
| Celgene Corporation | $52.41 | 2019 | |
| Incyte Corporation | $51.90 | 2019-2020 | |
| Genzyme Corporation | $46.77 | 2020-2022 | |
| Eisai INC. | $45.45 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $40.59 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $37.01 | 2019-2023 | Opdivo |
| Exelixis INC. | $30.33 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $29.02 | 2019 | |
| Emd Serono, INC. | $19.77 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.92 | 2022 | |
| Morphosys, US INC. | $16.50 | 2022 | |
| Glaxosmithkline, LLC. | $15.78 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $14.72 | 2019 | |
| Verastem, INC. | $13.49 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.